Trial reportAnnals of African medicine2026
Prevention of Pain on Propofol Injection: A Comparison of Pretreatment with 5-Hydroxytryptamine 3 Antagonists Granisetron, Ondansetron, and Ramosetron.
Trial report in Annals of African medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsPropofol is commonly used for the induction and maintenance of anesthesia. However, approximately 28%-90% of patients experience pain during injection. In this study, we compared the effectiveness of ondansetron, ramosetron, and granisetron, the three common 5-hydroxytryptamine 3 receptor antagonists in reducing the incidence and severity of propofol-induced pain (PIP).
methodsThis study included 120 adult patients (18-65 years old) scheduled for elective laparoscopic cholecystectomy under general anesthesia. Patients were randomly assigned to four groups ( n = 30 for each group). Granisetron (2 mg) was administered to Group G, ramosetron (0.3 mg) to Group R, ondansetron (4 mg) to Group O, and normal saline to Group N. Venous circulation was occluded by a rubber tourniquet to retain the drug in the vein and prevent its spread in circulation. Pain was assessed at 0, 5, 10, 15, and 20 s using a four-point verbal rating scale (VRS). The Kruskal-Wallis, Chi-square, Friedman tests, and generalized estimating equations were used to analyze the data.
resultsGroups O, R, and G demonstrated significantly reduced pain compared to group N at all-time points ( P < 0.001). Granisetron (Group G) was the most effective, with a mean VRS of 0.00 at 20 s. PIP incidence was 100% in Group N, compared to 80%, 70%, and 26.7% in Groups O, R, and G, respectively (χ² =40.443, P < 0.001).
conclusionGranisetron is the most effective in reducing PIP, though ondansetron and ramosetron also offer significant pain relief.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.